244 related articles for article (PubMed ID: 32272178)
1. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.
Zamani P; Navashenaq JG; Teymouri M; Karimi M; Mashreghi M; Jaafari MR
Life Sci; 2020 Jul; 252():117646. PubMed ID: 32272178
[TBL] [Abstract][Full Text] [Related]
2. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer.
Navashenaq JG; Zamani P; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Nanomedicine; 2020 Feb; 24():102150. PubMed ID: 31931230
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
5. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
[TBL] [Abstract][Full Text] [Related]
6. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
7. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
9. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
10. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
12. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
[TBL] [Abstract][Full Text] [Related]
13. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
14. Reducing Doxorubicin resistance in breast cancer by liposomal FOXM1 aptamer: In vitro and in vivo.
Ghandhariyoun N; Jaafari MR; Nikoofal-Sahlabadi S; Taghdisi SM; Moosavian SA
Life Sci; 2020 Dec; 262():118520. PubMed ID: 33010284
[TBL] [Abstract][Full Text] [Related]
15. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
16. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
17. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
18. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin.
Yahuafai J; Asai T; Nakamura G; Fukuta T; Siripong P; Hyodo K; Ishihara H; Kikuchi H; Oku N
J Control Release; 2014 Oct; 192():167-73. PubMed ID: 25041998
[TBL] [Abstract][Full Text] [Related]
19. Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.
Accardo A; Mannucci S; Nicolato E; Vurro F; Diaferia C; Bontempi P; Marzola P; Morelli G
Drug Deliv Transl Res; 2019 Feb; 9(1):215-226. PubMed ID: 30569349
[TBL] [Abstract][Full Text] [Related]
20. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
